{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=46",
    "query": {
      "intervention": "Formulation #2",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 1745,
    "total_pages": 175,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T17:03:28.767Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00391391",
      "title": "Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Orthomyxoviridae Infection",
        "Influenza",
        "Myxovirus Infection"
      ],
      "interventions": [
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "6 Months to 8 Years"
      },
      "enrollment_count": 520,
      "start_date": "2006-10",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2011-12-01",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 19,
      "location_summary": "Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more",
      "locations": [
        {
          "city": "Harrisburg",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Trumann",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00391391"
    },
    {
      "nct_id": "NCT00779233",
      "title": "Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Zidovudine tablets 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ranbaxy Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2004-09",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2008-10-24",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00779233"
    },
    {
      "nct_id": "NCT00387985",
      "title": "Bioequivalence Study in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MOA-728",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": null,
      "start_date": "2006-08",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 1,
      "location_summary": "Willingboro, New Jersey",
      "locations": [
        {
          "city": "Willingboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00387985"
    },
    {
      "nct_id": "NCT06702449",
      "title": "A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Candidate UTI vaccine low dose formulation 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine low dose formulation 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine medium dose formulation 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine medium dose formulation 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine high dose formulation 1",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine high dose formulation 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Candidate UTI vaccine HTD formulation 2",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 448,
      "start_date": "2024-11-19",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 6,
      "location_summary": "Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Secaucus",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Weatherford",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06702449"
    },
    {
      "nct_id": "NCT00117767",
      "title": "Terbinafine Compared to Griseofulvin in Children With Tinea Capitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tinea Capitis"
      ],
      "interventions": [
        {
          "name": "Terbinafine hydrochloride (HCl)",
          "type": "DRUG"
        },
        {
          "name": "Griseofulvin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 720,
      "start_date": "2004-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-05-31",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00117767"
    },
    {
      "nct_id": "NCT02783300",
      "title": "An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "GSK3326595",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 297,
      "start_date": "2016-08-30",
      "completion_date": "2023-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Miami, Florida • New York, New York + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02783300"
    },
    {
      "nct_id": "NCT06244316",
      "title": "A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "rhNGF 5 μg/mL",
          "type": "DRUG"
        },
        {
          "name": "rhNGF 10 μg/mL",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (Placebo solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 317,
      "start_date": "2024-01-22",
      "completion_date": "2024-12-04",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 10,
      "location_summary": "Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06244316"
    },
    {
      "nct_id": "NCT02258321",
      "title": "Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetic Assessments in Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PPI-668 tablet",
          "type": "DRUG"
        },
        {
          "name": "PPI-668 capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Presidio Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-10",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-22",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02258321"
    },
    {
      "nct_id": "NCT00403390",
      "title": "Generic vs. Name-Brand Levothyroxine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Congenital Hypothyroidism",
        "Hypothyroidism"
      ],
      "interventions": [
        {
          "name": "Brand Name Levothyroxine (Synthroid)",
          "type": "DRUG"
        },
        {
          "name": "Generic formulation of Levothyroxine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 34,
      "start_date": "2006-11",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403390"
    },
    {
      "nct_id": "NCT06641596",
      "title": "Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Overweight",
        "Metabolic Syndrome X"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Cr-400",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Cr-800",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "PE-500",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "PE-1000",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Kerry Group P.L.C",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 112,
      "start_date": "2019-02-01",
      "completion_date": "2024-05-29",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-11-07T17:03:28.767Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06641596"
    }
  ]
}